Displaying drugs 801 - 825 of 1296 in total
CMX-2043
CMX-2043 has been used in trials studying the treatment and prevention of Non STEMI, Unstable Angina, Stable Coronary Artery Disease, and Percutaneous Coronary Intervention.
Investigational
Matched Description: … Stable Coronary Artery Disease, and Percutaneous Coronary Intervention. ... CMX-2043 has been used in trials studying the treatment and prevention of Non STEMI, Unstable Angina, …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
SCB-2019
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.
The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. ... This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture ... company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and …
XMT-2056
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
INGN 201
INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Investigational
Matched Description: … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in ... combination with radiation and/or chemotherapy agents. ... replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and …
PRO 2000
PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce...
Investigational
Matched Description: … It is being studied for the prevention of HIV infection and other sexually transmitted diseases. ... This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing …
CAM-2029
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and …
AVXS-201
Withdrawn
OTX-2002
OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).
Investigational
Matched Description: … OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins …
ISB 2001
ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.
Investigational
Matched Description: … ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3. …
CLZ-2002
CLZ-2002 consists of allogeneic mesenchymal stem cells derived neuronal regeneration-promoting cells.
Investigational
Cortisone
A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)
Experimental
Matched Description: … It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. …
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Polysorbate 60
Experimental
Matched Synonyms: … PEG-20 sorbitan palmitostearate ... Polyoxyethylene (20) sorbitan monostearate ... Polyoxyethylene 20 sorbitan monostearate …
WRR-204
Experimental
CX-2009
CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
Investigational
Matched Description: … CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and …
ABO-202
Investigational
CRS-207
Investigational
TCN-202
Investigational
HMI-203
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
Investigational
SIG-207
SIG-207 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (alpha-Gal A), encapsulated within two-layer modified alginate spheres
Investigational
AMP-201
AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Investigational
ODM-207
Investigational
KAb201
Investigational
Odronextamab
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
Matched Description: … [A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, …
LX201
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Displaying drugs 801 - 825 of 1296 in total